The company has not filed an annual or quarterly report since its Q1 FY2023 10-Q, filed Aug 9, 2022. Its latest SEC filing is a 15-12G from Sep 30, 2022.
10-Q for Q1 FY2023, filed Aug 9, 2022
The sections below describe the company as of the FY2022 annual report.
Develops experimental cancer medicines for people with solid tumors and blood cancers, and evaluates a potential treatment for viral disease.
10-K for FY2022, filed May 25, 2022TYME is an emerging biotechnology company developing CMBTs that are intended to be effective across a broad range of solid tumors and…View ↗
The Company is currently focused on developing its novel compound, SM-88, as well as further evaluating its preclinical pipeline of novel…View ↗
TYME-19 is an oral synthetic member of the bile acid family. The Company also uses bile acids in its anti-cancer drug candidate, TYME-18.…View ↗
10-Q for Q1 FY2023, filed Aug 9, 2022
−$6.5MView ↗
8-K, filed Sep 16, 2022
On September 16, 2022 (the “Closing Date”), Tyme Technologies, Inc. (the “Company” or “Tyme”) completed its business combination with Syros…View ↗
8-K, filed Jul 5, 2022
On July 3, 2022, Tyme Technologies, Inc., a Delaware corporation (“Tyme”), entered into an Agreement and Plan of Merger (the “Merger…View ↗
A potential antiviral candidate
The latest report discusses an oral candidate being evaluated as a potential treatment for viral disease, alongside the cancer therapies described in the older report.
10-K for FY2019, filed Jun 12, 2019 10-K for FY2022, filed May 25, 2022TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM) that are intended to be effective across a…View ↗
Our lead clinical CMBT program, SM-88 (racemetyrosine), is a novel, oral, monotherapy investigational agent that has been studied in…View ↗
In addition to SM-88, the company has a pipeline of pre-Initial New Drug Application (“IND”) CMBT product candidates. One candidate…View ↗
Loading...
